New scan could replace radioactive tracers for cancer detection

NCT ID NCT06630845

Recruiting now Diagnosis Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares whole body diffusion-weighted MRI (DWI) to standard FDG PET/MRI scans in 30 adults with metastatic cancer. The goal is to see if DWI can spot cancer lesions as well as the PET scan, which uses a radioactive tracer. Participants will undergo both scans, and researchers will measure how many lesions each method finds and how consistent the readings are between doctors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fluorodeoxyglucose F18 (FDG)
What this could lead to: If successful, this could show that whole body DWI is as effective as FDG PET for spotting cancer spread, potentially reducing the need for radioactive tracers in some scans.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to all cancer types. The comparison is about imaging accuracy, not treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Show contact details

Locations

University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.